AG-270 - Moligand™,10mM in DMSO , CAS No.2201056-66-6

CAS: 2201056-66-6 Cat. No.: A655557 Formule: C30H27N5O2 Poids moléculaire: 489.57 PubChem CID: 134307820
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Taille
Allemagne (EU)
USA*
Prix
Qté
1ml
A655557-1ml
Sur commande · 8–12 semaines
572,62€
Enter a quantity for the sizes you want to add.

Vue d’ensemble

AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC 50 of 14 nM

In Vitro

AG-270 demonstrates potent reduction in levels of intracellular SAM , as well as MTAP-–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro. AG-270 exhibits an IC 50 of 20 nM in HCT116 MTAP- cell SAM at 72 h. MAT2A is a key enzyme in the methionine salvage pathway, responsible for generating the universal methyl donor, S-adenosylmethionine (SAM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AG-270 shows excellent microsomal, hepatocyte, and in vivo metabolic stability across species (human, mouse, rat, dog, and monkey). AG-270 exhibits T1/2 values of 5.9 h, 4.2 h, 4.8 h and 21.3 h in mouse, rat, monkey and dog, respectively . AG-270 (200 mg/kg, orally, q.d. for 38 days) results in dose-dependent reduction in tumor SAM levels and tumor growth of KP4 MTAP- xenografts and is well tolerated, with mean body weight loss <5% . Combining AG-270 with taxanes and gemcitabine yielded additive-tosynergistic antitumor activity, with the docetaxel combination yielding 50% complete tumor regressions in select models; combination benefits are observed in PDX models derived from esophageal, NSCLC, and pancreatic cancers. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Pancreatic KP4 MTAP - xenograft mouse model . Dosage: 10-200 mg/kg. Administration: Orally, q.d. for 38 days. Result: Led to dose-dependent reductions in tumor SAM levels and tumor growth of KP4 MTAP- xenografts (TGI = 36% (10 mg/kg), 48% (30 mg/kg), 66% (100 mg/kg), 67% (200 mg/kg).

IC50& Target:IC50: 14 nM (MAT2A)

Spécifications

Spécifications et pureté
Moligand™, 10mM in DMSO
Mécanismes biochimiques et physiologiques
AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC 50 of 14 nM.
Conditions de stockage de stockage
Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Grade
Moligand™
Noms et identifiants
Isomères SMILES
COC1=CC=C(C=C1)C2=C(N=C3C(=C(NN3C2=O)C4=CC=CC=C4)C5=CCCCC5)NC6=CC=CC=N6
CAS alternatif
2201056-66-6
PubChem CID
134307820
Poids moléculaire
489.57

Données avancées

Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

1 results found

Lot NumberCertificate TypeDateArticle
J2610916J2610916Certificate of AnalysisOct 15, 2026 A655557
FAQ et articles
Calculateurs de solution
Avis

Avis des clients

Besoin d'aide pour choisir la qualité ?

Notre guide de sélection des qualités couvre la pureté, le statut du stabilisant et l'adéquation à l'application pour toutes les variantes de notre catalogue.

Voir le guide des qualités Moligand™ →

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.